CoChat

Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction

Open access
Huet, Heather A, Growney, Joseph D, Johnson, Jennifer A, Li, Jing, Bilic, Sanela, Ostrom, Lance, Zafari, Mohammad, Kowal, Colleen, Yang, Guizhi, Royo, Axelle, Jensen, Michael, Dombrecht, Bruno, Meerschaert, Kris RA, Kolkman, Joost A, Cromie, Karen D, Mosher, Rebecca, Gao, Hui, Schuller, Alwin, Isaacs, Randi, Sellers, William R, Ettenberg, Seth A · 2014 · mAbs
Cited by 108

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Multiple therapeutic agonists of death receptor 5 (DR5) have been developed and are under clinical evaluation. Although these agonists demonstrate significant anti-tumor activity in preclinical models, the clinical efficacy in human cancer patients has been notably disappointing. One possible explanation might be that the current classes of therapeutic molecules are not sufficiently potent to elicit significant response in patients, particularly for dimeric antibody agonists that require secondary cross-linking via Fcγ receptors expressed on immune cells to achieve optimal clustering of DR5. To overcome this limitation, a novel multivalent Nanobody approach was taken with the goal of generating a significantly more potent DR5 agonist. In the present study, we show that trivalent DR5 targeting Nanobodies mimic the activity of natural ligand, and furthermore, increasing the valency of domains to tetramer and pentamer markedly increased potency of cell killing on tumor cells, with pentamers being more potent than tetramers in vitro. Increased potency was attributed to faster kinetics of death-inducing signaling complex assembly and caspase-8 and caspase-3 activation. In vivo, multivalent Nanobody molecules elicited superior anti-tumor activity compared to a conventional DR5 agonist antibody, including the ability to induce tumor regression in an insensitive patient-derived primary pancreatic tumor model. Furthermore, complete responses to Nanobody treatment were obtained in up to 50% of patient-derived primary pancreatic and colon tumor models, suggesting that multivalent DR5 Nanobodies may represent a significant new therapeutic modality for targeting death receptor signaling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4161/19420862.2014.975099

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 108

Metadata

Authors
Huet, H. A., Growney, J. D., Johnson, J. A., Li, J., Bilic, S., Ostrom, L., Zafari, M., Kowal, C., Yang, G., Royo, A., Jensen, M., Dombrecht, B., Meerschaert, K. R., Kolkman, J. A., Cromie, K. D., Mosher, R., Gao, H., Schuller, A., Isaacs, R., Sellers, W. R., & Ettenberg, S. A.
Venue
mAbs
Published
2014-10-30
Volume
6
Issue
6
Pages
1560-1570
ISSN
  • 1942-0862 (ISSN-L)
  • 1942-0870
OpenAlex
W2024971144
Cited by
108
References
2
FWCI
2.43
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. https://app.cochat.ai/papers/10.4161/19420862.2014.975099
The paper
Huet, H. A., Growney, J. D., Johnson, J. A., Li, J., Bilic, S., Ostrom, L., Zafari, M., Kowal, C., Yang, G., Royo, A., Jensen, M., Dombrecht, B., Meerschaert, K. R., Kolkman, J. A., Cromie, K. D., Mosher, R., Gao, H., Schuller, A., Isaacs, R., . . . Ettenberg, S. A. (2014). Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. mAbs. https://doi.org/10.4161/19420862.2014.975099

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.